367500-94-5

Basic information

• Product Name: 2-Carboxy-6-fluoroimidazo[1,2-a]pyridine
• Synonyms: 2-Carboxy-6-fluoroimidazo[1,2-a]pyridine;IMidazo[1,2-a]pyridine-2-carboxylic acid, 6-fluoro-
• CAS NO: 367500-94-5
• Molecular Formula: C₈H₅FN₂O₂
• Molecular Weight: 180.1359032
• Mol File: 367500-94-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Carboxy-6-fluoroimidazo[1,2-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Carboxy-6-fluoroimidazo[1,2-a]pyridine(367500-94-5)
• EPA Substance Registry System: 2-Carboxy-6-fluoroimidazo[1,2-a]pyridine(367500-94-5)

Safety Data

• Hazardous Substances Data: 367500-94-5(Hazardous Substances Data)

Usage

General Description

2-Carboxy-6-fluoroimidazo[1,2-a]pyridine is a chemical compound with the molecular formula C9H5FN2O2. It belongs to the class of organic compounds known as fluoroimidazoles, characterized by an imidazole ring where one or more carbon atoms are substituted by a fluorine atom. This specific chemical, having a fluorine atom and a carboxy group attached to the imidazole ring, has a wide range of potential applications in chemical research due to these functional groups. Detailed information about its physical characteristics, toxicity, or specific uses is limited, suggesting it's mainly used in specialized scientific research.

Upstream product

• 1341232-04-9 methyl 6-[(acetylamino)methyl]-5-chloro-2-(3-fluorophenyl)nicotinate 
• 1341231-96-6 methyl 5-chloro-6-cyano-2-(3-fluorophenyl)nicotinate 
• 1341232-15-2 methyl 2,5-dichloro-6-cyanonicotinate 
• 1341232-14-1 2,5-dichloro-3-(methoxycarbonyl)pyridine 1-oxide 
• 67754-03-4 methyl 2,5-dichloronicotinate 
• 59782-85-3 2,5-dichloronicotinic acid 
• 21717-96-4 2-amino-5-fluoropyridine 
• 367500-93-4 6-fluoro-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester 

Downstream Products

• 1610737-07-9 N-((1s,4s)-4-(2-(4'-(((3S,5R)-3,5-dimethylpiperazin-1-yl)methyl)biphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-6-fluoroimidazo[1,2-a]pyridine-2-carboxamide trifluoroacetic acid salt 
• 1610736-84-9 N-((1s,4s)-4-(2-(2'-((dimethylamino)methyl)-4'-hydroxybiphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-6-fluoroimidazo[1,2-a]pyridine-2-carboxamide trifluoroacetic acid salt 
• 1197289-06-7 N-((1s,4s)-4-(2-(2'-((1,4-oxazepan-4-yl)methyl)-4'-hydroxybiphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-6-fluoroimidazo[1,2-a]pyridine-2-carboxamide trifluoroacetic acid salt 
• 583881-21-4 C₂₂H₂₃Cl₂FN₄O₃ 
• 1038827-63-2 (6-fluoroimidazo[1,2-a]pyridin-2-yl)methanol 

Relevant articles and documents

Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents

A series of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides (IPAs), based on the structure of WZY02 discovered in our lab, were designed and synthesized as new anti-TB agents. Results reveal that many of them exhibit excellent in vitro inhibitory activity with low nanomolar MIC values against both drug-sensitive MTB strain H37Rv and drug-resistant clinical isolates. Compounds 15b and 15d display good safety and pharmacokinetic profiles, suggesting their promising potential to be lead compounds for future antitubercular drug discovery.

Synthesis and biological activities of indolizine derivatives as alpha-7 nAChR agonists

Human α7 nicotinic acetylcholine receptor (nAChR) is a promising therapeutic target for the treatment of schizophrenia accompanied with cognitive impairment. Herein, we report the synthesis and agonistic activities of a series of indolizine derivatives targeting to α7 nAChR. The results show that all synthesized compounds have affinity to α7 nAChR and some give strong agonistic activity, particularly most active agonists show higher potency than control EVP-6124. The docking and structure-activity relationship studies provide insights to develop more potent novel α7 nAChR agonists.

Chemical compounds

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.